Clinical Trial Update: Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions [NA]

View source ↗

Summary

This clinical trial update discusses the use of omalizumab as part of venom immunotherapy for bee venom allergy, with the trial status listed as unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bee Venom Allergy

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: The University Clinic of Pulmonary and Allergic Diseases Golnik | Conditions: Allergy, Bee Venom | NA | Status: UNKNOWN